Webinar | The Rare Treatment Accelerator: Feedback for Applicants
The first call for applications to the Rare Treatment Accelerator saw an extremely high volume of interest and quality of applications received. Following the review of applications by Healx’s selection panel, an initial three patient groups and their diseases were selected to progress to the next stage of the programme.
For those patient groups who have some – but not quite all – of the required components (such as data needed to power Healx’s AI algorithms and preclinical models to validate therapeutic predictions) we hosted this webinar to help attendees identify and address those elements in need of additional development.
This feedback webinar is suitable both for patient groups that applied to the Rare Treatment Accelerator and those who are considering applying in future.
During this 60-minute session, our team (also joined by Dan Lewi, CEO and Co-founder of the CATS Foundation) explore the following topics:
- Update on the Rare Treatment Accelerator: outcomes and next steps
- Review of RTA selection criteria (including data, preclinical, clinical and patient group considerations)
- How to prioritise which criteria to address first
- Where to find additional education / support resources
- Live Q&A session
You can watch the webinar recording below. We did our best to answer as many questions during the session, but if you have any additional ones for us please take a look at our FAQs section or submit them via email to email@example.com
Webinar | Rare Treatment Accelerator: Feedback for Applicants from Healx on Vimeo.
About the Rare Treatment Accelerator
The Rare Treatment Accelerator is a partnering programme that offers rare disease patient groups and Healx the opportunity to work together to quickly discover and develop repurposed treatments for rare diseases using AI.
Healx and selected applicants will combine their AI technology, data, disease and drug discovery expertise to develop novel repurposed therapies and move them towards the clinic within an expected timeframe of 24 months – with Healx contributing up to the value of $1 million in AI and drug discovery resources per project. For more information, please visit: https://www.healx.ai/rare-treatment-accelerator
Towards the end of the webinar (43:56) Dr Karine Proulx (Drug Discovery Alliance Manager – Patient Group Partnerships) shares a list of useful resources for patient groups. You can find links to these sources of additional support here:
– Cambridge Rare Disease Network (CRDN)
– Canadian Organization for Rare Disorders (CORD)
– National Organization for Rare Disorders (NORD)